Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed · Phase 2

Conditions studied: Cervical Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced, persistent, or recurrent cervical cancer.

Key facts

Study ID

NCT00016926

Run by

Gynecologic Oncology Group

Starts

2001-04-01

Last updated by the study team

2013-05-27

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Chao Family Comprehensive Cancer Center — Orange, California, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Holden Comprehensive Cancer Center — Iowa City, Iowa, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• University of Mississippi Medical Center — Jackson, Mississippi, United States
• Keesler Medical Center - Keesler AFB — Keesler Air Force Base, Mississippi, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• Brookview Research, Inc. — Nashville, Tennessee, United States
• University of Texas Medical Branch — Galveston, Texas, United States
• Norwegian Radium Hospital — Oslo, Norway

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.